Company: INDP
Filing Date: 2025-08-13
Form Type: S-3
Source: 0001641172-25-023499
Chunk: 14

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-08-13
Form: S-3
Chunk 14
---
 and investment power with respect to the shares of our common stock indicated as beneficially owned.

Except for the transactions described under “Prospectus Summary—August 2024 Financing,” “Prospectus Summary—November 2024 Financing” and “Prospectus Summary—January 2025 Financing,” the selling stockholders have not held any other position or office or had any other material relationship with us or our affiliates within the past three years.

As used in this prospectus, the term “selling stockholders” includes the selling stockholders named below and any donees, pledgees, transferees or other successors-in-interest selling shares of our common stock received after the date of this prospectus from the selling stockholders as a gift, pledge, or other non-sale related transfer.

The number of shares in the column “Shares of Common Stock Being Offered” represents all of the shares of our common stock that the selling stockholders may offer under this prospectus. The third and fourth columns assume the sale of all the shares of our common stock offered by the selling stockholders under this prospectus and that the selling stockholders do not acquire or dispose of any other shares of our common stock before the completion of the offering under this prospectus. However, because the selling stockholders may sell all or some of the shares offered under this prospectus from time to time, or in another permitted manner, we cannot assure you as to the actual number of shares of our common stock that will be sold by the selling stockholders or that will be held by the selling stockholders after completion of any sales. The selling stockholders may sell some, all or none of the shares of our common stock offered under this prospectus. We do not know how long the selling stockholders will hold the shares of our common stock offered under this prospectus before selling them, and we currently have no agreements, arrangements or understandings with the selling stockholders regarding the sale of any of the shares of our common stock.

Under the terms of the warrants, a selling stockholder may not exercise such warrants to the extent such exercise would cause such selling stockholder, together with its affiliates, to beneficially own a number of shares of common stock which would exceed 4.99% or 9.99% (depending on the individual stockholder) of our then outstanding common stock following such exercise. The number of shares does not reflect this limitation.

| 7 |

|                                                                                                   |     | Shares of Common   
 Stock Beneficially 
 Owned Prior to